Sjögren's Disease

Latest News


Latest Videos


CME Content


More News

(©michaelheim/Shutterstock.com)

Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.

B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.